4.6 Review

The EGAPP initiative: lessons learned

期刊

GENETICS IN MEDICINE
卷 16, 期 3, 页码 217-224

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/gim.2013.110

关键词

evidence-based medicine; genetics; guideline development; public health genomics; systematic review methods

资金

  1. National Institutes of Health [P50HG003374, RC2CA148570, UO1GM092676, UO1HG006507]
  2. Centers for Disease Control and Prevention [U18GD000005]
  3. Novartis

向作者/读者索取更多资源

The Evaluation of Genomic Applications in Practice and Prevention Working Group was first convened in 2005 to develop and test evidence-based methods for the evaluation of genomic tests in transition from research to clinical and public health practice. Over the ensuing years, the Working Group has met 26 times, publishing eight recommendation statements, two methods papers, and one outcomes paper, as well as planning and serving as technical experts on numerous associated systematic reviews. Evaluation of Genomic Applications in Practice and Prevention methods have evolved to address implications of the proliferation of genome-wide association studies and are currently expanding to face challenges expected from clinical implementation of whole-genome sequencing tests. In this article, we review the work of the Evaluation of Genomic Applications in Practice and Prevention Working Group over the first 8 years of its existence with an emphasis on lessons learned throughout the process. It is hoped that in addition to the published methods of the Working Group, the lessons we have learned along the way will be informative to others who are producers and consumers of evidence-based guidelines in the field of genomic medicine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据